124 related articles for article (PubMed ID: 10656221)
1. Gliclazide-induced acute hepatitis.
Dourakis SP; Tzemanakis E; Sinani C; Kafiri G; Hadziyannis SJ
Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):119-21. PubMed ID: 10656221
[TBL] [Abstract][Full Text] [Related]
2. Acute hepatitis associated with herb (Teucrium capitatum L.) administration.
Dourakis SP; Papanikolaou IS; Tzemanakis EN; Hadziyannis SJ
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):693-5. PubMed ID: 12072605
[TBL] [Abstract][Full Text] [Related]
3. Gliclazide-induced acute hepatitis with hypersensitivity features.
Chitturi S; Le V; Kench J; Loh C; George J
Dig Dis Sci; 2002 May; 47(5):1107-10. PubMed ID: 12018908
[No Abstract] [Full Text] [Related]
4. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
[TBL] [Abstract][Full Text] [Related]
5. Cholestatic liver injury after glimepiride therapy.
Chounta A; Zouridakis S; Ellinas C; Tsiodras S; Zoumpouli C; Kopanakis S; Giamarellou H
J Hepatol; 2005 Jun; 42(6):944-6. PubMed ID: 15885370
[TBL] [Abstract][Full Text] [Related]
6. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
May LD; Lefkowitch JH; Kram MT; Rubin DE
Ann Intern Med; 2002 Mar; 136(6):449-52. PubMed ID: 11900497
[TBL] [Abstract][Full Text] [Related]
7. Acute generalized exanthematous pustulosis induced by gliclazide: a case report.
Contreras-Steyls M; Vílchez-Márquez F; Mota A; Moyano B; Herrera-Ceballos E
Int J Dermatol; 2013 Dec; 52(12):1591-3. PubMed ID: 24261739
[No Abstract] [Full Text] [Related]
8. Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt.
Caksen H; Kendirci M; Tutuş A; Uzüm K; Kurtoğlu S
J Pediatr Endocrinol Metab; 2001; 14(8):1157-9. PubMed ID: 11592575
[TBL] [Abstract][Full Text] [Related]
9. Is gliclazide a sulfonylurea with difference? A review in 2016.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
[TBL] [Abstract][Full Text] [Related]
10. Second-generation thiazolidinediones and hepatotoxicity.
Marcy TR; Britton ML; Blevins SM
Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041
[TBL] [Abstract][Full Text] [Related]
11. Severe but reversible hepatitis induced by troglitazone.
Schiano T; Dolehide K; Hart J; Baker AL
Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
[No Abstract] [Full Text] [Related]
12. Glyburide-induced hepatitis.
Goodman RC; Dean PJ; Radparvar A; Kitabchi AE
Ann Intern Med; 1987 Jun; 106(6):837-9. PubMed ID: 3107448
[TBL] [Abstract][Full Text] [Related]
13. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
14. Is gliclazide a new antidiabetic drug implicated in the pathogenesis of ocular mucous membrane pemphigoid?
Cozzani E; Di Zenzo G; Cioni M; Javor S; Altieri M; Anselmi L; Parodi A
Eur J Dermatol; 2018 Jun; 28(3):396-397. PubMed ID: 29547128
[No Abstract] [Full Text] [Related]
15. Eosinophilic pleural effusion due to gliclazide.
Tzanakis N; Bouros D; Siafakas N
Respir Med; 2000 Jan; 94(1):94. PubMed ID: 10714487
[No Abstract] [Full Text] [Related]
16. Possible metformin-induced hepatotoxicity.
Kutoh E
Am J Geriatr Pharmacother; 2005 Dec; 3(4):270-3. PubMed ID: 16503324
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide induced acute hepototoxicity.
Jaiswal S; Mehta R; Musuku M; Tran L; McNamee W
JNMA J Nepal Med Assoc; 2009; 48(174):162-4. PubMed ID: 20387361
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].
Li GW; Pan CY; Gao Y; Yuan SY; Yang WY; Xing XY; Tian H; Guo XH; Li HB
Zhonghua Nei Ke Za Zhi; 2004 Jul; 43(7):510-4. PubMed ID: 15312405
[TBL] [Abstract][Full Text] [Related]
19. Probable hepatotoxicity associated with the use of metformin in type 2 diabetes.
Hashmi T
BMJ Case Rep; 2011 Sep; 2011():. PubMed ID: 22679227
[TBL] [Abstract][Full Text] [Related]
20. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
